27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
There was no significant difference in days spent at home between the specialist unit and standard care groups (median 51 v 45 days, 95% confidence interval for difference -12 to 24; P=0.3). 5 key findings →
Design: randomized controlled trial Participants: 600 Evidence: high
Full summary, score breakdown and related studies → Original source
The Vivifrail exercise programme provided significant benefits in functional capacity over usual-care. 3 key findings →
Design: randomized controlled trial Participants: 88 Evidence: high
Full summary, score breakdown and related studies → Original source
Aerobic exercise in early AD is associated with benefits in functional ability. 4 key findings →
Design: randomized controlled trial Participants: 68 Evidence: high
Full summary, score breakdown and related studies → Original source
The experimental paradigm was feasible and acceptable. 3 key findings →
Design: randomized controlled trial Participants: 95 Evidence: high
Full summary, score breakdown and related studies → Original source
Our evaluation study suggests that prophylactic treatment with low dose haloperidol in critically ill patients with a high risk for delirium probably has beneficial effects. 5 key findings →
Design: randomized controlled trial Participants: 299 Evidence: high
Full summary, score breakdown and related studies → Original source
It is believed that glycogen synthase kinase-3 (GSK-3) hyperphosphorylates tau protein in progressive supranuclear palsy (PSP). 1 key finding →
Design: randomized controlled trial Participants: 146 Evidence: high
Full summary, score breakdown and related studies → Original source
The use of light propofol sedation decreased the prevalence of postoperative delirium by 50% compared with deep sedation. 3 key findings →
Design: randomized controlled trial Participants: 114 Evidence: high
Full summary, score breakdown and related studies → Original source
15 care sites with 289 residents were randomly assigned. 2 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
Multifactorial intervention was not effective in preventing falls in older people with cognitive impairment and dementia presenting to the accident and emergency department after a fall. 2 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
Treatment of acutely sick, frail, older patients in a GEMU substantially reduced mortality. 2 key findings →
Design: randomized controlled trial Participants: 127 Evidence: high
Full summary, score breakdown and related studies → Original source
Purpose of the study The purpose of this study was to test the impact of Function-Focused Care for the Cognitively Impaired Intervention on nursing home residents with dementia and the nursing assistants who care for them. 2 key findings →
Design: randomized controlled trial Participants: 103 Evidence: high
Full summary, score breakdown and related studies → Original source
The optimal management of post-stroke cognitive impairment remains controversial. 1 key finding →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
A decision aid about feeding options in advanced dementia reduced decisional conflict for surrogates and increased their knowledge and communication about feeding options with providers. 1 key finding →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
Six inclusion criteria were identified for symptomatic therapy and neuroprotective trials: (1) diagnosis of RBD needs to satisfy the International Classification of Sleep Disorders, second edition, (ICSD-2) criteria; (2) minimum frequency of RBD episodes should preferably be ⩾2 times weekly to allow for assessment of change; (3) if the PD-RBD target population is included, it should be in the early stages of PD defined as Hoehn and Yahr stages 1-3 in Off (untreated); (4) iRBD patients with soft neurologic dysfunction and with operational criteria established by the consensus of study investigators; (5) patients with mild cognitive impairment (MCI); and (6) optimally treated comorbid OSA. 1 key finding →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
This study demonstrates that patients with dementia who suffer a hip fracture can benefit from multidisciplinary geriatric assessment and rehabilitation and should not be excluded from rehabilitation programs. 1 key finding →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
Forty-two case-control, cohort, and randomized trials were identified and included in the review. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
Clinical characteristics and demographics were similar between groups. 5 key findings →
Design: randomized controlled trial Participants: 89 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
PLWD also commonly experience social isolation (Shen et al., 2022), poorer physical function (Jehu et al., 2024a), worsened behavioral and psychological symptoms (Cerejeira et al., 2012), poorer quality of life (Cerejeira et al., 2012), and reduced access to healthcare (Mitchell et al., 2016) compared to older adults without dementia. 5 key findings →
Design: randomized controlled trial Participants: 21 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The MAINTAIN intervention demonstrated high fidelity in home assessments and intervention delivery, with participants receiving a mean of 15 of the 22 available sessions with a range of 5-25 sessions. 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →